The Latest Cardiac and Vascular News
Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA, May 7, 2020 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has initiated enrollment in the PROACT Xa clinical trial, a prospective, randomized, trial to determine if […]
Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA, Dec. 23, 2019 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received authorization from the U.S. Food and Drug Administration (FDA) pursuant to an Investigational New […]
ATLANTA, June 11, 2018 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, today announces the publication of our clinical study entitled “Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement” in a peer-reviewed medical journal, the Journal of the American College of Cardiology. The publication reports outcomes from […]
